In last trading session, Beam Therapeutics Inc (NASDAQ:BEAM) saw 1.25 million shares changing hands with its beta currently measuring 1.92. Company’s recent per share price level of $33.14 trading at -$0.95 or -2.79% at ring of the bell on the day assigns it a market valuation of $2.74B. That closing price of BEAM’s stock is at a discount of -49.37% from its 52-week high price of $49.50 and is indicating a premium of 37.12% from its 52-week low price of $20.84.
For Beam Therapeutics Inc (BEAM), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.76. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.22 in the current quarter.
Beam Therapeutics Inc (NASDAQ:BEAM) trade information
Upright in the red during last session for losing -2.79%, in the last five days BEAM remained trading in the green while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $33.14 price level, adding 5.99% to its value on the day. Beam Therapeutics Inc’s shares saw a change of 33.63% in year-to-date performance and have moved 16.00% in past 5-day. Beam Therapeutics Inc (NASDAQ:BEAM) showed a performance of 35.10% in past 30-days.
Wall Street analysts have assigned a consensus price target of 48 to the stock, which implies a rise of 30.96% to its current value. Analysts have been projecting 37 as a low price target for the stock while placing it at a high target of 69. It follows that stock’s current price would drop -11.65% in reaching the projected high whereas dropping to the targeted low would mean a loss of -11.65% for stock’s current value.
Beam Therapeutics Inc (BEAM) estimates and forecasts
This year revenue growth is estimated to fall -86.39% from the last financial year’s standing.
13 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 16.47M for the same. And 5 analysts are in estimates of company making revenue of 15.15M in the next quarter. Company posted 316.19M and 7.41M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.58% during past 5 years.
Beam Therapeutics Inc (NASDAQ:BEAM)’s Major holders
VANGUARD GROUP INC is the top institutional holder at BEAM for having 7.9 million shares of worth $185.11 million. And as of 2024-06-30, it was holding 9.6701 of the company’s outstanding shares.
The second largest institutional holder is FARALLON CAPITAL MANAGEMENT LLC, which was holding about 7.91 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6135 of outstanding shares, having a total worth of $185.4 million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 4.78 shares of worth $158.46 million or 5.77% of the total outstanding shares. The later fund manager was in possession of 2.34 shares on Sep 30, 2024 , making its stake of worth around $77.45 million in the company or a holder of 2.82% of company’s stock.
